Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 9/20 | 0.58 |
| ▸ | TPSAB1 | Q15661 | 3/20 | 0.58 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.58 |
| ▸ | F2 | P00734 | 2/20 | 0.58 |
| ▸ | PLG | P00747 | 1/20 | 0.58 |
| ▸ | PLAU | P00749 | 1/20 | 0.58 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.58 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.58 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.57 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.57 |
| ▸ | F7 | P08709 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | PKM | P14618 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL548407 | 0.95 | F10 (0.60) | F10TPSAB1PRSS1F2PLG | |
| SCHEMBL548419 | 0.92 | F10 (0.63) | F10TPSAB1PRSS1F2PLG | |
| SCHEMBL5329624 | 0.91 | F10 (0.50) | F10TPSAB1PRSS1F2PLG | |
| SCHEMBL28757174 | 0.88 | F10 (0.76) | F10TPSAB1PRSS1F2PLG | |
| SCHEMBL29625940 | 0.88 | F10 (0.76) | F10TPSAB1PRSS1F2PLG | |
| SCHEMBL27639305 | 0.87 | F10 (0.57) | F10TPSAB1PRSS1F2PLG | |
| SCHEMBL65730 | 0.86 | F10 (0.77) | F10TPSAB1PRSS1F2PLG | |
| SCHEMBL7479169 | 0.86 | F10 (0.71) | F10TPSAB1PRSS1F2PLG | |
| SCHEMBL4322200 | 0.85 | TPSAB1 (0.78) | F10TPSAB1PRSS1F2PLG | |
| SCHEMBL7477342 | 0.85 | F10 (0.64) | F10TPSAB1PRSS1F2PLG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070099905-A1 | Combinations of drugs for the treatment of neoplasms | BORISY ALEXIS | 2007-05-03 | — | — | US | claimed |
| CN-1829509-A | Pharmaceutical composition for treating tumors | COMBINATORX INC (US) | 2006-09-06 | — | — | CN | claimed |
| US-20050080075-A1 | Formulations, conjugates, and combinations of drugs for the treatment of neoplasms | COMBINATORX, INC. | 2005-04-14 | — | — | US | claimed |
| US-20050054708-A1 | Combinations of drugs for the treatment of neoplasms | COMINATORX, INCORPORATED | 2005-03-10 | — | — | US | claimed |
| US-20040116407-A1 | Combinations of drugs for the treatment of neoplasms | COMBINATORX, INC. | 2004-06-17 | — | — | US | claimed |
| WO-2004006849-A2 | COMBINATIONS OF DRUGS FOR THE TREATMENT OF NEOPLASMS | COMBINATORX, INCORPORATED (US) | 2004-01-22 | — | — | WO | claimed |
| EP-1891013-B1 | TETRAHYDROQUINOLINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2014-07-23 | — | — | EP | disclosed |
| US-8524732-B2 | Substituted tetrahydroquinolines | MERCK PATENT GMBH (DE) | 2013-09-03 | — | — | US | disclosed |
| EP-2121700-B1 | SUBSTITUTED TETRAHYDROQUINOLINES | MERCK PATENT GMBH (DE) | 2012-10-03 | — | — | EP | disclosed |
| US-8207345-B2 | Antitumor agents; use in combination with other drugs such as pentamidine | MERCK PATENT GMBH (DE) | 2012-06-26 | — | — | US | disclosed |
| US-20120130147-A1 | METHODS FOR THE TREATMENT OF TUMORS WITH INDANE COMPOUNDS | FINSINGER DIRK (DE) | 2012-05-24 | — | — | US | disclosed |
| US-8110583-B2 | treatment of tumors; 1,5-bis(4'-(N-hydroxyamidino)phenoxy)pentane; maintain cells in the G2/M cell cycle | MERCK PATENT GMBH (DE) | 2012-02-07 | — | — | US | disclosed |
| EP-2033959-B1 | Tetrahydropyranoquinoline derivatives | MERCK PATENT GMBH (DE) | 2011-04-27 | — | — | EP | disclosed |
| US-20050054708-A1 | Combinations of drugs for the treatment of neoplasms | COMINATORX, INCORPORATED | 2005-03-10 | — | — | US | disclosed |
| US-20040116407-A1 | Combinations of drugs for the treatment of neoplasms | COMBINATORX, INC. | 2004-06-17 | — | — | US | disclosed |
| WO-2004006842-A2 | COMBINATIONS OF DRUGS FOR THE TREATMENT OF NEOPLASMS | COMBINATORX, INCORPORATED (US) | 2004-01-22 | — | — | WO | disclosed |
| WO-2004006849-A2 | COMBINATIONS OF DRUGS FOR THE TREATMENT OF NEOPLASMS | COMBINATORX, INCORPORATED (US) | 2004-01-22 | — | — | WO | disclosed |
| EP-0664703-B1 | METHODS OF COMBATING (PNEUMOCYSTIS CARINII) PNEUMONIA AND COMPOUNDS USEFUL THEREFOR | UNIV NORTH CAROLINA (US) | 1999-12-15 | — | — | EP | disclosed |
| US-5578631-A | BACTERICIDES | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 1996-11-26 | — | — | US | disclosed |
| US-5428051-A | Side effect reduction; nontoxic; bis-benzimidazole compounds | UNIVERSITY OF NORTH CAROLINA (US) | 1995-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120130147-A1 | METHODS FOR THE TREATMENT OF TUMORS WITH INDANE COMPOUNDS | TP53, IDH3A, IDH2 | F10 1961/4885TPSAB1 1889/4885PRSS1 3740/4885 |
| US-20050080075-A1 | Formulations, conjugates, and combinations of drugs for the treatment of neoplasms | ABCB1, SLCO1B3, SLCO1B1 | F10 4333/4885TPSAB1 1403/4885PRSS1 3168/4885 |
| US-20070099905-A1 | Combinations of drugs for the treatment of neoplasms | VHL, NRAS, MYC | F10 2519/4885TPSAB1 1230/4885PRSS1 2212/4885 |
| US-20050054708-A1 | Combinations of drugs for the treatment of neoplasms | TYMP, DPYD, DHFR | F10 3617/4885TPSAB1 1037/4885PRSS1 1458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.